Pancreatic β Cell–specific Expression of Thioredoxin, an Antioxidative and Antiapoptotic Protein, Prevents Autoimmune and Streptozotocin-induced Diabetes

By Mizuo Hotta,*‡ Fumi Tashiro,* Hiroshi Ikegami,‡ Hitoshi Niwa,* Toshio Ogihara,‡ Junji Yodoi,§ and Jun-ichi Miyazaki*

From the * Department of Nutrition and Physiological Chemistry, and the ‡ Department of Geriatric Medicine, Osaka University Medical School, Osaka 565-0871, Japan; and the § Department of Biological Responses, Institute for Virus Research, Kyoto University, Kyoto 606-8397, Japan

Summary

The cytotoxicity of reactive oxygen intermediates (ROIs) has been implicated in the destruction of pancreatic β cells in insulin-dependent diabetes mellitus (IDDM). Thioredoxin (TRX), a redox (reduction/oxidation)-active protein, has recently been shown to protect cells from oxidative stress and apoptosis. To elucidate the roles of oxidative stress in the development of autoimmune diabetes in vivo, we produced nonobese diabetic transgenic mice that overexpress TRX in their pancreatic β cells. In these transgenic mice, the incidence of diabetes was markedly reduced, whereas the development of insulitis was not prevented. Moreover, induction of diabetes by streptozotocin, an ROI-generating agent, was also attenuated by TRX overexpression in β cells. This is the first direct demonstration that an antioxidative and antiapoptotic protein protects β cells in vivo against both autoimmune and drug-induced diabetes. Our results strongly suggest that oxidative stress plays an essential role in the destruction of β cells by infiltrating inflammatory cells in IDDM.

Key words: oxidative stress • nonobese diabetic mouse • insulitis • cytokine • apoptosis

Insulin-dependent diabetes mellitus (IDDM) is caused by the autoimmune destruction of insulin-producing pancreatic β cells (1). By the clinical onset of this disease, β cells are almost completely gone, requiring affected individuals to inject insulin daily to sustain their lives. Nonobese diabetic (NOD) mice spontaneously develop autoimmune diabetes with remarkable similarity to human IDDM (2; for a review, see reference 3). A common pathological feature is the infiltration of inflammatory cells into the islets, termed insulitis, followed by the selective destruction of β cells. Infiltrating cells are composed of T and B lymphocytes, macrophages, and NK cells, among which T cells and macrophages are believed to play the major role in β cell destruction. However, the molecular mechanisms of β cell destruction by these infiltrating cells are poorly understood. Elucidation of these mechanisms is important not only for understanding the pathogenesis of IDDM and other autoimmune diseases, but also for developing effective means of preventing these diseases. Several reports have suggested that locally produced reactive oxygen intermediates (ROIs) are involved in these effector mechanisms of β cell destruction (4–9). In vitro, ROIs such as nitric oxide (NO), hydroxyl radical (OH·), hydrogen peroxide (H2O2), and superoxide radical (O2·−) were shown to be induced in β cells by cytokines such as IL-1, IFN-γ, and TNF-α, which are known to be secreted by T cells and macrophages that infiltrate the islets (5–9). ROIs either administered exogenously or induced in β cells by cytokines have been shown to cause the destruction of β cells in vitro, and apoptosis has recently been suggested to be the mechanism involved (10–14). Among endocrine cells in pancreatic islets, insulin-producing cells appear particularly vulnerable to oxidative stress, probably due to their low levels of key enzymes that scavenge ROIs (15–19). Therefore, the targeted expression of antioxidative and antiapoptotic molecules in pancreatic β cells would be expected to protect them from destruction and to prevent the development of IDDM.

Thioredoxin (TRX) is a low molecular mass (~12 kD) redox (reduction/oxidation)-active protein found in both prokaryotic and eukaryotic cells (for a review, see reference...
This protein has a conserved active site containing cysteine residues that are reversibly reduced by the NADPH-dependent seleno-flavoprotein, thioredoxin reductase (TRX), originally studied as a reducing cofactor for ribonucleotide reductase (22), is one of the essential proteins in DNA synthesis and repair (23-25). Recent studies showed that TRX is induced by various types of stress, such as viral infection, ischemic insult, UV light, x-ray irradiation, and H$_2$O$_2$, that it acts as a scavenger of ROIs, and that it can repair proteins oxidized by ROIs (for a review, see references 20 and 26). In vitro studies have demonstrated a protective effect of TRX against the cytotoxicity of ROIs (26). An augmented expression of TRX is often observed in neoplastic cells (26, 27) and appears to attenuate the cytotoxicity of ROIs (for a review, see references 30 and 31), such as nuclear factor kappaB, activator factor 1 (AP-1), and nuclear redox factor 1 (Ref-1) (24, 26, 32-34).

To directly assess the implications of oxidative stress in pancreatic beta cell destruction in autoimmune diabetes, we have generated NOD transgenic mice with targeted overexpression of the antioxidant protein, TRX, in pancreatic beta cells. The protective effect of TRX against beta cell destruction was also tested in experimental diabetes induced by the ROI-generating agent, streptozotocin (STZ). Pancreatic beta cells were significantly protected from destruction in both models, indicating the involvement of oxidative stress and apoptosis in the destruction of beta cells in autoimmune as well as STZ-induced diabetes.

Materials and Methods

Construction of the TRX Transgene. The Ins-TRX transgene (Fig. 1) consisted of the human insulin promoter (35), the rabbit globin gene, and human TRX cDNA inserted at the unique collagenase (Sigma Chemical Co., St. Louis, MO) digestion of the pancreas, followed by Ficoll 400 (Amersham Pharmacia Biotech, Uppsala, Sweden) density gradient purification (38).

Western Blotting. Isolated islets and dissected pancreata were lysed in lysis buffer (0.15 M NaCl, 10 mM Tris-HCl, pH 7.4, and 1% N-P-40) with a protease inhibitor, PMSF, and were appropriately diluted with cold PBS for immunoblotting. Protein concentration was determined using a protein assay kit (Bio-Rad Laboratories, Inc., South San Francisco, CA). The lysates were incubated at 100°C for 5 min with a third volume of the sample buffer (75 mM Tris-HCl, pH 6.8, 6% SDS, 15% glycerol, 15% 2-ME, and 0.015% bromophenol blue). These samples were subjected to electrophoresis on a SDS/15% polyacrylamide gel and electrophoretically transferred onto a polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA). To assess the levels of human TRX expression, known amounts of recombinant human TRX (>95% pure) prepared from human TRX-producing Escherichia coli (39) were simultaneously loaded on the gel. Mouse anti-human TRX mAb provided by Fujirebio Inc. (Tokyo, Japan) was used as a probe to detect human TRX. Endogenous murine TRX was detected using rabbit anti–murine TRX polyclonal Ab raised against a synthetic polypeptide of the COOH-terminal 10 amino acid residues of murine TRX. This Ab recognized murine TRX but not human TRX (J. Yodoi, unpublished data). The second Ab was rabbit anti–mouse IgG Ab or goat anti–rabbit IgG Ab conjugated with horseradish peroxidase (both from Zymed Laboratories Inc., South San Francisco, CA). Human and murine TRX were visualized using an ECL detection kit (Amersham Pharmacia Biotech).

Islet Secretion for Islets. Isolated islets of 12-wk-old (NOD × B6) F1 transgenic mice, their nontransgenic littermates, and BALB/c mice (CLEA Japan Inc.) were anesthetized with an intraperitoneal injection of pentobarbital. Pancreatic islets were isolated by stationary collagenase (Sigma Chemical Co., St. Louis, MO) digestion of the pancreas.
batch incubation method (40). Each batch of 10 islets was incubated at 37°C for 3 h in Kребs-Ringer solution containing 0.3% BSA with 3 different glucose concentrations. Five batches of transgenic and nontransgenic islets were simultaneously tested at each glucose concentration (5, 10, and 25 mM). After removal of the islets, the insulin concentration of each batch was determined using a mouse insulin ELISA kit (Seikagaku Corp., Tokyo, Japan).

Diagnosis of Diabetes. Female NOD transgenic mice (F2, F3) and their nontransgenic littermates were monitored from 12 wk of age with weekly measurements of urine glucose using TesTape (Eli Lilly and Company, Indianapolis, IN). When mice were glucosuric for two consecutive weeks, they were diagnosed as diabetic.

Evaluation of Insulitis. Pancreata were removed from 12-wk-old female NOD transgenic mice (line 90, n = 10) and their TRX-negative littermates (n = 8), and were fixed with 20% formalin. After paraffin-embedded fixation, 3-μm slices of each pancreas were prepared for hematoxylin and eosin staining. 25 islets of each pancreas were randomly chosen for microscopic examination of insulitis. According to the classification system of Kurasawa et al. (41), each islet was scored as follows: 0, an islet without infiltration; 1, <25% area of an islet was occupied by immunocytes; 2, ≥25 and <50%; 3, ≥50%.

Production of STZ-induced Diabetic Mice. STZ (Wako Pure Chemical Industries Ltd., Osaka, Japan) was dissolved in 0.05 M citrate buffer (pH 4.5; reference 42), and immediately injected intraperitoneally into 8-wk-old (NOD × B6) F1 transgenic mice and their TRX-negative littermates at a dose of 250 mg/kg. These islets were isolated from (NOD × B6) F1 transgenic mice, which were produced by intercrossing female B6 mice with male NOD transgenic mice of each strain. Western blot analysis using a human TRX-specific mAb as probe showed a high level of human TRX expression in the transgenic islets of lines 21 and 90 (Fig. 3, top). For this analysis, 15 μg of islet protein was loaded on each lane. By comparing the densities of these bands with those of known amounts of recombinant human TRX (Fig. 3, top), the ratio of human TRX to total protein in the islets was estimated to be 1.7 ng/μg in both lines 21 and 90. Al-
although human TRX was not detectable in the islets of line 48, prolonged exposure of the membrane revealed a low-level expression of human TRX in these mice (not shown). The expression of endogenous murine TRX was also examined by Western blot analysis using rabbit anti-mouse TRX serum as the probe, which was not reactive with human TRX. The levels of endogenous TRX expression were found to be much lower in the islets than in the pancreas (Fig. 3, bottom).

Insulin Secretory Capacities of Transgenic Islets. We next examined whether transgenic TRX expression in β cells affects glucose-responsive insulin secretion. The insulin secretory capacities of (NOD × B6) F1 transgenic islets at three glucose concentrations (5, 10, and 25 mM) were 0.40 ± 0.05, 1.02 ± 0.08, and 2.76 ± 0.15 ng/h/islet (mean ± SD), respectively. The insulin secretory capacities of nontransgenic littermates were 0.43 ± 0.03, 1.04 ± 0.07, and 2.83 ± 0.13 ng/h/islet, respectively. There was no significant difference between results from the islets of transgenic mice and those of their TRX-negative littermates at any glucose concentration (unpaired t-test, NS for all), indicating that the overexpression of TRX did not affect the insulin secretory capacity of β cells.

Incidence of Diabetes. To examine the effect of TRX expression on the development of diabetes, female NOD transgenic mice and their nontransgenic littermates were monitored for glucosuria up to 32 wk of age. In transgenic mice of lines 21 and 90, the cumulative incidence of diabetes was markedly reduced at 32 wk of age (Fig. 4). Statistical analysis demonstrated a significant difference between NOD transgenic mice and their TRX-negative littermates (Kaplan-Meier method, P < 0.01 for both), but not in line 48 (NS).

Blood Glucose Levels and Insulin Content after STZ Injection. We next examined whether TRX overexpression confers resistance to STZ-induced diabetes. In this experiment, we used (NOD × B6) F1 transgenic mice and their nontransgenic littermates to avoid the complications in interpretation that could arise from the autoimmune diabetes accompanying the NOD background. No evidence of insulitis was observed in these mice. Before STZ treatment, fasting blood glucose levels were 80.0 ± 5.7 mg/dl for transgenic mice (n = 9) and 77.6 ± 9.7 mg/dl for their TRX-negative littermates (n = 9). 7 d after STZ injection, blood glucose levels were >500 mg/dl in most of the nontransgenic mice, but were only moderately elevated in TRX transgenic mice, as shown in Fig. 5 a. There was a significant difference in blood glucose levels between the transgenic mice and their TRX-negative littermates. We
next examined the insulin content of the pancreas of STZ-treated transgenic and nontransgenic littersates after subjecting them to a 6-h fast (Fig. 5 b). Pancreatic insulin content was significantly higher in the transgenic mice (21.8 ± 9.4 ng/mg pancreatic weight; n = 5) than in their TRX-negative littersates (8.2 ± 4.2 ng/mg; n = 5). Without STZ treatment, insulin content was the same for the transgenic mice (66 ± 7.0 ng/mg; n = 5) and those TRX-negative littersates (63.0 ± 8.6 ng/mg; n = 5). These results clearly indicate that human TRX overexpression protects β cells from the cytotoxicity caused by STZ administration.

Discussion

IDDM is characterized by the infiltration of lymphocytes into the pancreatic islets followed by the destruction of β cells, which leads to overt diabetes. However, it is not well understood how β cells are destroyed by the immunocytes in islets. The coexistence of various cell types and their complex interactions in the inflammatory islets make it very difficult to study the mechanism of β cell destruction in vivo. To overcome this complexity, we adopted a strategy in which molecules that have been assumed to affect β cell destruction are directly tested by overexpressing them specifically in β cells in vivo. In this study, we have generated NOD transgenic mice that express human TRX, which has strong antioxidative and antiapoptotic activity (20, 26). Analysis by RT-PCR demonstrated that human TRX was expressed exclusively in the islets of our transgenic mice. Immunoblot analysis showed that the ratio of human TRX to total protein of the transgenic islets was 1.7 ng/μg (Fig. 3, top). The endogenous TRX levels of normal organs are less than 0.3 ng/μg (I. Yodoi, unpublished data). Therefore, the TRX levels in transgenic islets are considerably higher than those of normal tissues. An excessive expression of TRX may be toxic to cells, as pointed out by Baker et al. (44). However, we consider this an unlikely problem in our transgenic mice because endogenous TRX expression is often enhanced to 0.3–2 ng/μg or more (28, 45) in immature, transformed, or neoplastic cells (26–29, 44, 45).

The targeted overexpression of TRX in pancreatic β cells remarkably reduced the incidence of diabetes (Fig. 4), indicating a protective effect of TRX against the autoimmune destruction of β cells. Destruction of β cells induced by the ROI-generating agent STZ was also attenuated by TRX overexpression, as evidenced by lower blood glucose levels and higher insulin content in TRX-transgenic mice than in their TRX-negative littersates. These results indicate that the overexpression of the antioxidative molecule TRX in β cells confers protective effects against spontaneous autoimmune diabetes as well as experimental diabetes induced by STZ. Recently, Kubisch et al. (46) reported that the overexpression of Drosophila Cu/Zn superoxide dismutase, a superoxide-scavenging enzyme, in β cells confers resistance to experimental diabetes induced by alloxan. Taken together, these results strongly suggest that ROIs play major roles in the β cell destruction that accompanies not only experimental diabetes induced by the ROI-generating drugs STZ and alloxan, but also the spontaneous autoimmune diabetes of the NOD mouse.

Our study revealed that the expression of endogenous TRX is very low in islet cells compared with pancreatic exocrine cells (Fig. 3, bottom). Previously, Hansson et al. (47) suggested that a lower expression of TRX occurs in islet cells than in pancreatic exocrine cells, although their immunohistochemical analysis was not quantitative. They also showed that TRX expression was suppressed in recently fed mice. This attenuation of TRX expression in insulin-secreting β cells may be one of the reasons β cells are highly susceptible to oxidative stress. Recent studies have indicated a stepwise development of autoimmune diabetes, with insulitis the first phase and massive destruction of β cells the second (48). We showed that there was no significant difference in the severity of insulitis between NOD transgenic mice and their TRX-negative littersates, indicating that overexpression of TRX did not prevent insulitis, but rather attenuated the cytotoxicity of the infiltrating immunocytes in islets. This result is consistent with the function of TRX as an antioxidative protein. It has also been reported that IDDM develops without insulitis in transgenic mice overexpressing inducible NO synthase (iNOS) in β cells (49), probably through the increased oxidative stress due to NO production. This report and our present study together suggest that oxidative stress is one of the major effector mechanisms of β cell destruction by infiltrating inflammatory cells.

Recently, apoptosis has also been suggested as a pivotal mechanism of β cell destruction in autoimmune (12–13) and drug-induced diabetes (14, 50). The Fas/FasL system has been implicated in β cell apoptosis. NOD transgenic mice that express FasL in their β cells were reported to be highly susceptible to autoimmune diabetes (12), whereas Fas-deficient NOD-lpr/lpr mice were resistant to autoimmune diabetes (12, 13). Recombinant TRX has been reported to protect cells against apoptosis mediated by both TNF and anti-Fas agonistic Ab (51). Very recently, mammalian TRX has been shown to function as a direct inhibitor of apoptosis signal-regulating kinase (ASK)-1 (52). These results suggest that the antiapoptotic function of TRX may also participate in the protection of β cells after immunocytic infiltration.

Although β cell–targeted overexpression of TRX effectively suppressed the incidence of autoimmune diabetes in NOD mice, a low percentage of transgenic mice still developed diabetes with significantly later onset. At present, we can only speculate on the molecular mechanisms causing diabetes in these mice. It is probable that TRX could not confer complete resistance to the oxidative stress and β cell death caused by infiltrating cells. Alternatively, other secondary mechanisms for β cell destruction, such as the perforin-dependent cytotoxicity of CD8+ T cells (53), might have led to the autoimmune diabetogenic β cell loss.

In human IDDM, overt diabetes develops when β cells are almost completely destroyed. Subjects at high risk for the future development of IDDM can only be identified by the presence of autoantibodies, which indicate the presence
of autoimmunity and probable ongoing β cell destruction. The prevention of and intervention in IDDM is only possible during the second phase of the autoimmune process. Therefore, these effects of TRX overexpression suggest a new approach to protecting subjects in the second phase of IDDM or to delaying the development of overt diabetes.

This study provides the first direct evidence that an antioxidative and antiapoptotic protein has protective effects on autoimmune diabetes. Our results strongly suggest that oxidative stress plays an essential role in β cell destruction caused by inflammatory cells in islets. The results also suggest an antioxidative and antiapoptotic strategy as a promising approach for the prevention of and intervention in IDDM in particular, as well as other autoimmune diseases in general, in subjects with ongoing autoimmunity.

The authors thank Ms. R. Takano and Drs. H. Aihara, J. Kawagishi, T. Kobayashi, and Y. Nitta for the generation of transgenic mice. We are grateful to Drs. Y. Takagi, Y. Ueda, and E. Yamato for helpful advice.

This work was supported by grants-in-aid from the Japanese Ministry of Education, Science, Sports, and Culture.

Address correspondence to Jun-ichi Miyazaki, Department of Nutrition and Physiological Chemistry, Osaka University Medical School, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Phone: 81-6-879-3820; Fax: 81-6-879-3829; E-mail: jimiyaza@nutri.med.osaka-u.ac.jp

Received for publication 29 June 1998 and in revised form 4 August 1998.

References

1. Gepts, W. 1965. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 14:619–633.
2. Makino, S., K. Kunimoto, Y. Murakami, Y. Mizushima, K. Katagiri, and Y. Tochino. 1980. Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu. 29:1–13.
3. Kikutani, H., and S. Makino. 1992. The murine autoimmune diabetes model: NOD and related strains. Adv. Immunol. 51:285–322.
4. Grankvist, K., S. Marklund, J. Sehlin, and I.B. Taljedal. 1979. Superoxide dismutase, catalase and scavengers of hydroxyl radical protect against the toxic action of aloxan on pancreatic islet cells in vitro. Biochem. J. 182:17–25.
5. Kroncke, K.D., V. Kolb-Bachofen, B. Berschick, V. Burkart, and H. Kolb. 1991. Activated macrophages kill pancreatic syngeneic islet cells via arginine-dependent nitric oxide generation. Biochem. Biophys. Res. Commun. 175:752–758.
6. Corbett, J.A., A.L. Wang, M.A. Sweetland, J.R. Lancaster, Jr., and M.L. McDaniel. 1992. Interleukin-1 beta induces the formation of nitric oxide by beta-cells purified from rodent islets of Langerhans. Evidence for the beta-cell as a source and site of action of nitric oxide. J. Clin. Invest. 90:2384–2391.
7. Mandrup-Poulsen, T. 1996. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia. 39:1005–1029.
8. Ezirik, D.L., M. Flodstrom, A.E. Karlson, and N. Wehsl. 1996. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic beta cells. Diabetologia. 39:875–890.
9. Rabinovitch, A., W.L. Suarez-Pinzon, O. Sorensen, and R.C. Bleackley. 1996. Inducible nitric oxide synthase (iNOS) in pancreatic islets of nonobese diabetic mice: identification of iNOS-expressing cells and relationships to cytokines expressed in the islets. Endocrinology. 137:2093–2099.
10. Kurrer, M.O., S.V. Pakala, H.L. Hanson, and J.D. Katz. 1997. Beta cell apoptosis in T cell-mediated autoimmune diabetes. Proc. Natl. Acad. Sci. USA. 94:213–218.
11. O’Brien, B.A., B.V. Harmon, D.P. Cameron, and D.J. Allan. 1997. Apoptosis is the mode of beta cell death responsible for the development of IDDM in the nonobese diabetic (NOD) mouse. Diabetes. 46:750–757.
12. Chervovsky, A.V., Y. Wang, F.S. Wong, I. Visintin, R.A. Flavell, C.A. Janeway, Jr., and L.A. Mabbs. 1997. The role of Fas in autoimmune diabetes. Cell. 89:17–24.
13. Itoh, N., A. Imagawa, T. Hanafusa, M. Waguri, K. Yamamoto, H. Iwashashi, M. Moriwaki, H. Nakajima, J. Miyagawa, M. Namba, et al. 1997. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186:613–618.
14. Kaneto, H., H. Fujii, H.G. Seo, K. Suzuki, T. Matsuoka, M. Nakamura, H. Tatsumi, Y. Yamasaki, T. Kamada, and N. Taniguchi. 1995. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes. 44:753–758.
15. Grankvist, K., S.L. Marklund, and I.B. Taljedal. 1981. Cu/Zn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem. J. 199:393–398.
16. Gandy, S.E., R.R. Galbrath, R.K. Crouch, M.G. Buse, and G.M. Galbrath. 1981. Superoxide dismutases in human islets of Langerhans. J. Exp. Med. 154:1457–1548.
17. Malaisse, W.J., F. Malaisse-Lagae, A. Sener, and D.G. Pipeleers. 1982. Determinants of the selective toxicity of alloxan to the pancreatic beta cell. Proc. Natl. Acad. Sci. USA. 79:927–930.
18. Cornelius, J.G., B.G. Luttge, and A.B. Peck. 1993. Antioxidant enzyme activities in IDDM-prone and IDDM-resistant mice: a comparative study. Free Radic. Biol. Med. 14:409–420.
19. Lenzen, S., J. Dringkern, and M. Tiedge. 1996. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. 20:463–466.
20. Holmgren, A. 1985. Thioredoxin. Annu. Rev. Biochem. 54:237–271.
21. Luthman, M., and A. Holmgren. 1982. R at liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry. 21:6628–6633.
22. Laurent, T.C., E.C. Moore, and P. Richard. 1964. Enzymatic synthesis of deoxyribonucleotides. IV. Isolation and
characterization of thioredoxin, the hydrogen donor from Escherichia coli. B. J. Biol. Chem. 239:3436–3444.

23. Huber, H.E., M. Russel, P. Model, and C.C. Richardson. 1986. Interaction of mutant thioredoxins of Escherichia coli with the gene 5 protein of phage TT7. The redox capacity of thioredoxin is not required for stimulation of DNA polymerase activity. J. Biol. Chem. 261:15006–15012.

24. Hirota, K., M. Matsui, S. Iwata, A. Nishiyama, K. Mori, and J. Yodoi. 1997. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. U.S.A. 94:3633–3638.

25. Steitz, T.A. 1998. A mechanism for all polymerases. J. Biol. Chem. 273:2493–2496.

26. Schenk, H., M. Klein, W. Erdbrugger, W. Droge, and K. Schulze-Osthoff. 1994. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κappa B and AP-1. Proc. Natl. Acad. Sci. U.S.A. 91:1672–1676.

27. Berggren, M., A. Gallegos, J.R. Gasdaska, P.Y. Gasdaska, J. Wanneke, and G. Powis. 1996. Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:3459–3466.

28. Sasada, T., T. Iwata, N. Sato, Y. Kitaoka, T. Nakamura, A. Nishiyama, Y. Taniguchi, A. Takabayashi, and J. Yodoi. 1996. Redox control of resistance to cis-diaminedichloroplatinum (II) (CDDP): protective effect of human thioredoxin against CDDP-induced cytotoxicity. J. Clin. Invest. 97:2268–2276.

29. Yokomizo, A., M. Nono, H. Nanni, Y. Makino, T. Ohga, M. Wada, T. Okamoto, J. Yodoi, M. Kuwano, and K. Kohno. 1995. Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res. 55:4293–4296.

30. Sonenshein, G.E. 1997. Redox control of the regulation of thioredoxin reductase activity in cancer cells by the chemopreventive agent sele

31. Karin, M., Z.G. Liu, and E. Zandi. 1997. AP-1 function and the control of apoptosis. Semin. Cancer Biol. 8:113–119.

32. Schenck, H., M. Klein, W. Erdbrugger, W. Droge, and K. Schulze-Osthoff. 1994. Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κappa B and AP-1. Proc. Natl. Acad. Sci. U.S.A. 91:1672–1676.

33. Qin, J., G.M. Clore, W.M. Kennedy, J.R. Huth, and A.M. Gronenborn. 1995. Solution structure of human thioredoxin in a mixed disulfide intermediate complex with its target peptide from the transcription factor NF kappa B. Structure (London). 3:289–297.

34. Qin, J., G.M. Clore, W.P. Kennedy, J. Kuszwewski, and A.M. Gronenborn. 1996. The solution structure of human thioredoxin complexed with its target from Ref-1 reveals peptide chain reversal. Structure (London). 4:613–620.

35. Miyazaki, J., K. Araki, E. Yamato, H. Ikogami, T. Asano, Y. Shibasaki, Y. Koka, and K. Yamamura. 1990. Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: special reference to expression of glucose transporter isoforms. Endocrinology. 127:126–132.

36. Gordon, J.W., and F.H. Ruddle. 1983. Gene transfer into mouse embryos production of transgenic mice by pronuclear injection. Methods Enzymol. 101:411–433.

37. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156–159.

38. Gotot, M., T. Maki, T. Kiyozumi, S. Satomi, and A.P. Monaco. 1985. An improved method for isolation of mouse pancreatic islets. Transplantation (Baltimore). 40:437–438.

39. Mitsui, A., T. Hirakawa, and J. Yodoi. 1992. Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin. Biochem. Biophys. Res. Commun. 186:1220–1226.

40. Nakamura, K., N. Akamuro, M. Takabayashi, H. Tomioka, I. Toto, and S. Yoshida. 1990. The immunosuppres

41. Kurasawa, M., Y. Yonekura, S. Takasawa, and H. Okamoto. 1998. Transgenic mice overexpressing type 2 nitric-oxide synthase protects pancreatic beta-cells against oxidative stress. Diabetes. 46:1563–1566.

42. Hansson, H.A., A. Holmgren, B. Oezel, and I.B. Taljedal. 1986. Immunohistochemical localization of thioredoxin and thioredoxin reductase in mouse exocrine and endocrine pancreas. Cell. Immunol. 245:2493–2496.

43. Andre, I., M. Gonzalez, B. Wang, J. Katz, C. Benoist, and D. Mathis. 1996. Checkpoints in the progression of autoimmune disease: lessons from diabetes models. Proc. Natl. Acad. Sci. U.S.A. 93:2260–2263.

44. Takamura, T., I. Kato, N. Kimura, T. Nakazawa, H. Yonekura, S. Takasawa, and H. Okamoto. 1998. Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis. J. Biol. Chem. 273:2493–2496.

45. Morgan, N.G., H.C. Cable, N.R. Newcombe, and G.T. Williams. 1994. Treatment of cultured pancreatic B-cells with streptozotocin induces cell death by apoptosis. Biosci. Rep. 14:243–250.

46. Miwa, M., H. Matsumoto, H. Nakamura, M. Miyajima, A. Yamauchi, S. I. Yehara, A. Ichida, K. Kida, A. Horiiuchi, and J. Yodoi. 1995. Protective activity of adult T cell leukemia-derived factor (ADIF) against tumor necrosis factor-dependent cytotoxicity on U937 cells. J. Immunol. 154:3837–3841.

47. Saijo, M., N. Ishihara, M. Fujii, K. Takeda, K. Tobi, and J. Yodoi. 1996. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J. Exp. Med. 186:989–997.